13F Insight
DOSSIER · 13F-HR · Q2 2026

Casdin Capital, LLC

$2.0B in tracked AUM across 43 positions as of Q2 2026.

CC
CIK 0001534261 · last filed Jun 30, 2026
Total AUM
$2.0B
as of Q2 2026
Holdings
43
—
positions
Whale Score
72
72
strong
Activity
—
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Casdin Capital, LLC SEC 13F Filing (Q3 2025)
Portfolio Overview

Casdin Capital’s filing for the period ending September 30, 2025, reveals a concentrated, high-conviction portfolio with a specific focus on the life sciences sector. The total portfolio value decreased slightly by 2.8%, settling at $1.07 billion, down from $1.10 billion in the previous quarter. The fund maintains a relatively compact list of 26 holdings, indicating a strategy that favors depth over b...

The portfolio is characterized by high concentration risk, with the top three positions accounting for approximately 58% of the total assets. This structure suggests an investment approach that relies on deep fundamental research in specific niches rather than broad market diversification. The management appears willing to hold significant stakes in fewer companies, implying high confidence in their scientific and commercial prospects.

Key Holdings

The portfolio is dominated by GENEDX HOLDINGS CORP (WGS), which stands as the largest holding with a value of $323.99 million, representing 30.37% of the portfolio. While the position saw a minor reduction of 14.3% (approximately $245.54K), it remains the anchor of the fund's strategy.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
RVMD
REVOLUTION MEDICINES INC
$483M2.6M24.2%02
RLAY
RELAY THERAPEUTICS INC
$300M16.0M15.0%03
WGS
GENEDX HOLDINGS CORP
$254M3.7M12.7%04
BLFS
BIOLIFE SOLUTIONS INC
$131M4.7M6.6%05
ILMN
ILLUMINA INC
$93M530K4.7%06
LAB
STANDARD BIOTOOLS INC
$73M88.8M3.7%07
GPCR
STRUCTURE THERAPEUTICS INC
$63M1.2M3.2%08
DNLI
DENALI THERAPEUTICS INC
$53M2.0M2.6%09
NGNE
NEUROGENE INC
$49M1.5M2.4%10
BEAM
BEAM THERAPEUTICS INC
$46M1.4M2.3%

Filing history

2026Q2Jun 30
$2.0B▲ 51.3%
43 positionsView →2026Q1Mar 31
$1.3B▼ 18.0%
40 positionsView →2025Q4Dec 31
$1.6B▲ 50.9%
38 positionsView →2025Q3Sep 30
$1.1B▼ 2.8%
26 positionsView →2025Q2Jun 30
$1.1B▲ 4.2%
33 positionsLocked2025Q1Mar 31
$1.1B▼ 29.9%
35 positionsLocked2024Q4Dec 31
$1.5B▲ 0.2%
39 positionsLocked2024Q3Sep 30
$1.5B▲ 14.5%
35 positionsLocked2024Q2Jun 30
$1.3B▼ 2.6%
38 positionsLocked2024Q1Mar 31
$1.3B▲ 32.0%
37 positionsLocked2023Q4Dec 31
$1.0B▲ 12.8%
38 positionsLocked2023Q3Sep 30
$904M▼ 21.0%
40 positionsLocked
Showing 12 of 41